Crestchem Ltd Stock Falls to 52-Week Low of Rs.84.05 Amid Continued Downtrend

Recent Price Movements and Market Context

On 2 Feb 2026, Crestchem opened with a notable gap up of 8.12%, reaching an intraday high of Rs.92. Despite this early strength, the stock reversed course and closed at its new 52-week low of Rs.84.05. This closing price represents a 1.22% decline on the day and continues a two-day losing streak that has resulted in a cumulative return of -5.88% over this short span. The stock marginally outperformed its sector by 0.4% today, yet remains well below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent downward momentum.

The broader market environment showed resilience, with the Sensex recovering from an initial drop of 167.26 points to close 291.65 points higher at 80,847.33, a 0.15% gain. Mega-cap stocks led this recovery, while some indices such as the S&P BSE FMCG and NIFTY FMCG also hit new 52-week lows, indicating sector-specific pressures amid a mixed market backdrop.

Long-Term Performance and Fundamental Assessment

Over the last twelve months, Crestchem Ltd has experienced a significant decline of 68.10%, a stark contrast to the Sensex’s positive 4.25% return. This underperformance extends beyond the one-year horizon, with the stock also lagging the BSE500 index over the last three years and the past three months. The stock’s 52-week high was Rs.329, underscoring the magnitude of the recent price erosion.

From a fundamental perspective, Crestchem’s long-term growth in operating profits has been modest, with a compound annual growth rate (CAGR) of 19.73% over the past five years. However, the company’s ability to service its debt remains constrained, reflected in a low average EBIT to interest ratio of 1.75. This ratio indicates limited earnings buffer to cover interest expenses, which may weigh on financial flexibility.

The company reported flat results in the half-year ended September 2025, with a return on capital employed (ROCE) at a relatively low 32.96%, the lowest in recent periods. This figure suggests subdued efficiency in generating returns from capital investments. Despite these challenges, Crestchem maintains a return on equity (ROE) of 25%, which is considered attractive within its sector.

Valuation and Shareholding Structure

In terms of valuation, Crestchem trades at a price-to-book value of 3.4, which is viewed as reasonable when compared to its peers’ historical averages. This valuation reflects a balance between the company’s earnings potential and the risks associated with its recent performance trends.

The majority of Crestchem’s shares are held by non-institutional investors, which may influence trading dynamics and liquidity. The company’s market capitalisation grade stands at 4, indicating a mid-sized market presence within the Specialty Chemicals sector.

Sector and Market Dynamics

The Specialty Chemicals sector, to which Crestchem belongs, has faced mixed fortunes recently. While some indices within the broader market have rebounded, others, including FMCG-related indices, have also recorded new lows. Crestchem’s performance relative to its sector peers has been subdued, with the stock’s Mojo Score at 26.0 and a recent downgrade from a Sell to a Strong Sell rating on 20 Jan 2026. This downgrade reflects a reassessment of the company’s risk profile and growth prospects based on current data.

Despite the stock’s recent underperformance, it remains a notable constituent within the Specialty Chemicals sector, which continues to be influenced by global supply chain factors, raw material price fluctuations, and regulatory developments. Crestchem’s stock price action and fundamental metrics suggest that the company is navigating a challenging environment, with several headwinds impacting investor sentiment and valuation.

Profitability Trends and Recent Financial Results

Over the past year, Crestchem’s profits have declined by 36.3%, a significant contraction that has contributed to the stock’s downward trajectory. The company’s flat half-year results in September 2025 further underscore the subdued earnings environment. The combination of declining profits and a challenging debt servicing capacity has weighed on the stock’s market performance.

While Crestchem’s ROE remains relatively strong at 25%, the overall financial metrics point to a company facing headwinds in both growth and profitability. The stock’s current trading levels, well below all major moving averages, reflect these concerns and the market’s cautious stance.

Summary of Key Metrics

To summarise, Crestchem Ltd’s key data points as of 2 Feb 2026 include:

• New 52-week low price: Rs.84.05
• 52-week high price: Rs.329
• One-year return: -68.10%
• Mojo Score: 26.0 (Strong Sell, downgraded from Sell on 20 Jan 2026)
• Operating profit CAGR (5 years): 19.73%
• EBIT to interest ratio (average): 1.75
• ROCE (HY): 32.96%
• ROE: 25%
• Price to Book Value: 3.4
• Market Cap Grade: 4

These figures illustrate the stock’s current valuation and performance challenges within the Specialty Chemicals sector and the broader market context.

Conclusion

Crestchem Ltd’s fall to a new 52-week low of Rs.84.05 marks a continuation of a significant downtrend that has persisted over the past year. The stock’s performance has been impacted by a combination of declining profits, constrained debt servicing ability, and subdued returns on capital. While the broader market has shown resilience, Crestchem’s valuation and fundamental metrics reflect ongoing pressures within its sector and company-specific factors. The recent downgrade to a Strong Sell rating further highlights the cautious outlook based on current data.

Investors and market participants will continue to monitor Crestchem’s financial results and sector developments as the company navigates this challenging phase.

Unlock special upgrade rates for a limited period. Start Saving Now →